Elevar Therapeutics

Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.

Angus Liu Sep 25, 2026 9:38am

In landmark for Korean biotech, Elevar wins FDA nod for Lyrfigtu

Sep 24, 2026 11:25am

Legend Biotech, Merck, Otsuka—Fierce Pharma Asia

Jul 31, 2026 9:00am

2 FDA citations trouble Hengrui, Elevar’s liver cancer combo

Jul 28, 2026 3:02pm

GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia

Jul 17, 2026 9:38am

FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time

Jul 10, 2026 10:55am